Drug Approval | November 16, 2023
Imfinzi plus chemotherapy approved in China as for metastatic biliary tract cancer
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient
General Medicine grows 5% and Vaccines 10% led by Shingrix
Rocuronium Bromide Injection had estimated annual sales of USD 54 million in the US (IQVIA MAT August 2023).
India is following a holistic and inclusive approach in alignment with the vison of Universal Health Coverage and the resolute commitment to ‘leave no one behind
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
ASMD is highly variable and the age of onset, specific symptoms and severity of the disorder can vary dramatically from one person to another
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Pant delivers keynote address at National Conclave on “Augmented Zoonotic Diseases Surveillance at Human – Wildlife Interface”
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Venus Remedies' oncology wing has also secured marketing authorisation from Myanmar for another chemotherapy drug
Subscribe To Our Newsletter & Stay Updated
